XLF-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products

European Journal of Pharmacology

Volumn 627, Issue 1-3, 2010, Pages 340-347

  Li, Hongyan ^a   Zheng, Xuguang ^a   Wang, Hongbo ^a   Zhang, Yi ^a   Xin, Hongqi ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Advanced glycation end products (AGE); Collagen IV; Connective tissue growth factor (CTGF); Diabetic nephropathy; Fibronectin; N carboxymethyl AGE (CML AGE); Transforming growth factor 1 (TGF 1); XLF III 43

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; COUMARIN DERIVATIVE; FIBRONECTIN; GLUCOSE; LYSOZYME; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UREA; XLF 3 43;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWNSTREAM PROCESSING; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; FIBRINOLYSIS; GLOMERULOSCLEROSIS; GLYCATION; IN VITRO STUDY; KIDNEY HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN SYNTHESIS INHIBITION; RAT; STREPTOZOCIN DIABETES; STRUCTURE ANALYSIS; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION;

ANIMALS; BODY WEIGHT; COUMARINS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FEMALE; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERGLYCEMIA; HYPERTENSION; KIDNEY; RATS; RATS, SPRAGUE-DAWLEY; SALICYLIC ACIDS;

EID: 73449136312     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.065     Document Type: Article

References (53)

1. Ahmed N. Advanced glycation endproducts - role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 67 (2005) 3-21
2. Ahmed N., and Thornalley P.J. Advanced glycation endproducts: what is their relevance to diabetic complications?. Diabetes Obes. Metab. 9 (2007) 233-245
3. Barnett A. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am. J. Med. 119 5 Suppl 1 (2006) S40-S47
4. Bitzer M., Sterzel R.B., and Bottinger E.P. Transforming growth factor-beta in renal disease. Kidney Blood Press. Res. 21 (1998) 1-12
5. Bohlender J.M., Franke S., Steinand G., and Wolf G. Advanced glycation end products and the kidney. Am. J. Physiol. Renal Physiol. 289 (2005) F645-F659
6. Bolton W.K., Cattran D.C., Williams M.E., Adler S.G., Appel G.B., Cartwright K., Foiles P.G., Freedmang B.I., Raskinh P., Ratneri R.E., Spinowitzk B.S., Whittierl F.C., and Wuerth J.P. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24 (2004) 32-40
7. Bucala R. Lipid and lipoprotein modification by advanced glycosylation end-products: role in atherosclerosis. Exp. Physiol. 82 (1997) 327-337
8. Bucala R., Model P., and Cerami A. Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc. Natl. Acad. Sci. 81 (1984) 105-109
9. Chen S., Jim B., and Ziyadeh F.N. Diabetic nephropathy and transforming growth factor-beta: our view of glomerulosclerosis and fibrosis build-up. Semin. Nephrol. 23 (2003) 532-543
10. Cooper M.E., Thallas V., Forbes J., Scalbert E., Sastra S., Darby I., and Soulis T. The cross-link breaker prevents vascular advanced glycation end-product accumulation. Diabetologia 43 (2000) 660-664
11. Desai K., and Wu L. Methylglyoxal and advanced glycation endproducts: new therapeutic horizons. Recent Patents on Cardiovasc. Drug Discov. 2 (2007) 89-99
12. Figarola J.L., Scott S., Loera S., Xi B., Synold T., Weiss L., and Rahbar S. Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. Diabetes Metab. Res. Rev. 21 (2005) 533-544
13. Figarola J.L., Scott S., Loera S., Xi B., Synold T., and Rahbar S. Renoprotective and lipid-lowering effects of LR compounds, novel advanced glycation end product inhibitors, in streptozotocin-induced diabetic rats. Ann. N.Y. Acad. Sci. 1043 (2005) 767-776
14. Forbes J.M., Thallas V., Thomas M.C., Founds H.W., Burns W.C., Jerums G., and Cooper M.E. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 17 (2003) 1762-1764
15. Fukami S., Yamagishi S., Ueda S., and Okuda S. Role of AGE in diabetic nephropathy. Curr. Pharm. Des. 14 (2008) 946-952
16. Gibert R.E., Cox A., Wu L.L., Allen T.J., Hulthen U.L., Jerums G., and Cooper M.E. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 47 (1998) 414-422
17. Gibert R.E., Akdeniz A., Weitz S., Usinger W.R., Molineaux C., Jones S.E., Langham R.G., and Jerums G. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 26 (2003) 2632-2636
18. Goh S.Y., and Cooper M.E. The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 93 (2008) 1143-1152
19. Goh S.Y., Jasik M., and Cooper M.E. Agents in development for the treatment of diabetic nephropathy. Expert Opin. Emerg. Drugs 13 (2008) 447-463
20. Gross J.L., Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., and Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28 (2005) 176-188
21. Ikeda K., Higashi T., Sano H., Jinnouchi Y., Yoshida M.., Araki T., Ueda S., and Horiuchi S. N (epsilon)- (carboxymethyl) lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35 (1996) 8075-8083
22. Jafarmejad A., Bathaie S.Z., Nakhjavani M., and Hassan M. Investigation of the mechanisms involved in the high-dose and long-term acetyl salicylic acid therapy of type I diabetic rats. J. Pharmacol. Exp. Ther. 324 (2008) 850-857
23. Kanwar Y.S., Wada J., Sun L., Xie P., Wallner E.I., Chen S., Sumant Chugh S., and Danesh F.R. Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. 233 (2008) 4-11
24. Mankhey R.W., Bhatti F., and Maric C. 17β-estrogen replacement improves renal function and pathology associated with diabetic nephropathy. Am. J. Physiol. Renal Physol. 288 (2005) F399-F405
25. Miyata T., Ueda Y., Asahi K., Izuhara Y., Inagi R., Saito A., Strihou C.V.Y.D., and Kurokawa K. Mechanism of the inhibitory effect of OPB-9195 [(6)-2-Isopropylidenehydrazono-4-oxo-thiazolidin-5- ylacetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J. Am. Soc. Nephrol. 11 (2000) 1719-1725
26. Myint K.M., Yamamoto Y., Doi T., Kato I., Harashima A., Yonekura H., Watanabe T., Shinohara H., Takeuchi M., Tsuneyama K., Hashimoto N., Asano M., Takasawa S., Okamato H., and Yamamoto H. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55 (2006) 2510-2522
27. Nakamura S., Makita Z., Ishikawa S., Yasumura K., Fujii W., Yanagisawa K., Kawata T., and Koike T. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46 (1997) 895-899
28. Nakamura S., Li H., Adijiang A., Pischetsrieder M., and Niwa T. Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol. Dial. Transplant. 22 (2007) 2165-2174
29. Osicka T.M., Yu Y., Panagiotopoulos S., Clavant S.P., Kiriazis Z., Pike R.N., Pratt L.M., Russo L.M., Kemp B.E., Comper W.D., and Jerums G. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 49 (2000) 87-93
30. Peppa M., Uribarri J., and Vlassara H. Glucose, advanced glycation end products, and diabetes complications: what is new and what works. Clin. Diabetes 21 (2003) 186-187
31. Peppa M., Brem H., Cai W., Zhang J.G., Basgen J., Li Z., Vlassara H., and Uribarri J. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT711). Am. J. Nephrol. 26 (2006) 430-436
32. Peyroux J., and Sternberg M. Advanced glycation endproducts (AGE) pharmacological inhibition in diabetes. Pathol. Biol. 54 (2006) 405-419
33. Rahbar S. Novel inhibitors of glycation and AGE formation. Cell Biochem. Biophys. 48 (2007) 147-157
34. Ramasamy R., Vannucci S.J., Yan S.S., Herold K., Yan S.F., and Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration and inflammation. Glycobiology 15 (2005) 16R-28R
35. Reddy V.P., and Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov.Today 11 (2006) 646-665
36. Reddy S., Bichler J., Wells-Knecht K.J., Thorpe S.R., and Baynes J.W. N-(Carboxymethyl) lysine is a dominant advanced glycation end product (AGE) s antigen in tissue proteins. Biochemistry 34 (1995) 10872-10878
37. Rossini A., Like A., Dulin W., and Cahill G.J. Pancreatic beta cell toxicity by streptozotocin anomers. Diabetes 26 (1977) 1120-1124
38. Schena F.P., and Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. 16 (2005) S30-S33
39. Tajiri Y., Möller C., and Grill V. AGE flurosclerosis long term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits cell function. Endocrinology 138 (1997) 273-280
40. Tanji N., Markowitz G.S., Fu C., Kislinger T., Taguchi A., Pischetsrieder M., Stern D., Schmidt A.M., and D'agati V.D. Expression of advanced glycation end products and their cellular receptor rage in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 11 (2000) 1656-1666
41. Thomas M.C., Fordes J.M., and Cooper M.E. Advanced glycation end products and diabetic nephropathy. Am. J. Ther. 12 (2005) 562-572
42. Thornalley P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 419 (2003) 31-40
43. Vasan S., Zhang X., Zhang X., Kapurniotu A., Bernhagen J., Teichberg S., Basgen J., Wagle D., Shih D., Terlecky I., Bucala R., Cerami A., Egan J., and Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382 (1996) 275-278
44. Vinson J.A., and Howard T.B. Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J. Nutri. Biochem. 7 (1996) 659-663
45. Voziyan P.A., and Hudson B.G. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann. N.Y. Acad. Sci. 1043 (2005) 807-816
46. Wahab N.A., Yevdokimova N., Weston B.S., Roberts T., Li X.J., Brinkman H., and Mason R.M. Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem. J. 359 (2001) 77-87
47. Wahab N.A., Weaton B.S., Roberts T., and Mason R.M. Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J. Am. Soc. Nephrol. 13 (2002) 2437-2445
48. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., Bucciarelli L.G., Rong L.L., Moser B., Markowitz G.S., Stein G., Bierhaus A., Liliensiek B., Arnold B., Nawroth P.P., Stern D.M., D'Agati V.D., and Schmidt A.M. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162 (2003) 1123-1137
49. Williams M.E. Clinical studies of advanced glycation end products and diabetic kidney disease. Curr. Diabetes Rep. 4 (2004) 441-446
50. Yang S., Litchfield J.E., and Baynes J.W. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch. Biochem. Biophys. 412 (2003) 42-46
51. Youssef S., Nguyen D.T., Soulis T., Pangiotopoulos S., Jerums G., and Cooper M.E. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int. 55 (1999) 907-916
52. Zhou G., Li C., and Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. A J Pathol. 165 (2004) 2033-2043
53. Ziyadeh F.N. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J. Am. Soc. Nephrol. 15 (2004) S55-S57